Liu Jie, Liu Jifang, Chai Xiaofeng, Zhu Huijuan, Xing Bing, Lian Wei, Lian Xiaolan, Duan Lian, Deng Kan, Yao Yong
Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Pituitary Center of Innovative Medicine, Peking Union Medical College Hospital, Beijing, China.
Endocrine. 2025 Jun 8. doi: 10.1007/s12020-025-04298-5.
Thyrotropin (TSH)-secreting pituitary adenomas, though a rare cause of hyperthyroidism, present significant challenges in management. This study aimed to assess surgical outcomes, remission factors, and postoperative complications.
In this largest single-center retrospective study, we analyzed 177 TSHoma surgical patients (2001-2022), with 152 cases selected for long-term follow-up. Primary outcome was remission; secondary outcomes included postoperative infection and hypopituitarism.
The overall remission rate was 72.4%. Radiologically, patients with Knosp Grade 3-4 tumors (OR = 12.95, 95% CI: 3.65-53.77, p < 0.001), suprasellar involvement (OR = 8.61, 95% CI: 2.66-31.37, p < 0.001) significantly elevated the risk of non-remission. Asymptomatic hyperthyroid TSHomas, despite the absence of overt hyperthyroidism symptoms, comprise 24.3% of cases and are characterized by a significantly lower remission rate (54.1%) compared to mild (82.8%) and severe hyperthyroidism (73.7%), accompanied by larger tumor size [26.0 (19.0-30.0) mm], increased cavernous sinus involvement (38.9%), and more extensive suprasellar extension (43.2%). Postoperative TSH level ≤ 0.183 µIU/ml (AUC 0.752, sensitivity 80.0%, specificity 69.7%) and tumor maximum diameter ≤ 21.5 mm remission (AUC 0.858, sensitivity 81.9%, specificity 81.8%) can serve as simple predictors for remission. The rate of postoperative complications was 7.7% for CNS infection and 15.1% for hypopituitarism, respectively. Notably, CSF leakage significantly elevated the risk of postoperative infection (OR = 37.30, 95% CI: 5.58-507.77, p = 0.001) and hypopituitarism (OR = 5.43, 95% CI: 1.67-18.97, p = 0.006).
Surgical intervention for TSHoma demonstrates a promising remission rate. Asymptomatic TSHomas should be exclusively cautious due to their significantly lower remission rates. CSF leakage correlates with an increased risk of both postoperative infection and hypopituitarism.
促甲状腺激素(TSH)分泌型垂体腺瘤虽然是甲状腺功能亢进症的罕见病因,但在治疗方面存在重大挑战。本研究旨在评估手术效果、缓解因素和术后并发症。
在这项最大规模的单中心回顾性研究中,我们分析了177例TSH瘤手术患者(2001 - 2022年),其中152例入选长期随访。主要结局是缓解;次要结局包括术后感染和垂体功能减退。
总体缓解率为72.4%。影像学上,Knosp 3 - 4级肿瘤患者(OR = 12.95,95%CI:3.65 - 53.77,p < 0.001)、鞍上受累患者(OR = 8.61,95%CI:2.66 - 31.37,p < 0.001)的未缓解风险显著升高。无症状性甲状腺功能亢进TSH瘤,尽管没有明显的甲状腺功能亢进症状,但占病例的24.3%,其缓解率(54.1%)显著低于轻度(82.8%)和重度甲状腺功能亢进(73.7%),伴有更大的肿瘤大小[26.0(19.0 - 30.0)mm]、海绵窦受累增加(38.9%)和更广泛的鞍上扩展(43.2%)。术后TSH水平≤0.183 μIU/ml(AUC 0.752,敏感性80.0%,特异性69.7%)和肿瘤最大直径≤21.5 mm缓解(AUC 0.858,敏感性81.9%,特异性81.8%)可作为缓解的简单预测指标。术后中枢神经系统感染并发症发生率为7.7%,垂体功能减退并发症发生率为15.1%。值得注意的是,脑脊液漏显著增加了术后感染(OR = 37.30,95%CI:5.58 - 507.77,p = 0.001)和垂体功能减退(OR = 5.43,95%CI:1.67 - 18.97,p = 0.006)的风险。
TSH瘤的手术干预显示出有希望的缓解率。无症状TSH瘤因其显著较低的缓解率应格外谨慎。脑脊液漏与术后感染和垂体功能减退风险增加相关。